Articles From: Bonterra Energy Corp. Enters Into An Agreement with Canada Revenue Agency With Regard to Its Conversion From A Trust To A Corporation to Florida 4-H and UnitedHealthcare Expand “Eat4-Health” Partnership, Use “Pedal Power” to Help Tackle Obesity and Encourage Healthy Lifestyles Among Youth


http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0981188001&sourceType=1 http://media3.marketwire.com/logos/20140627-BONT.jpg CALGARY, ALBERTA --
Sign-up for Bonterra Energy Corp. Enters Into An Agreement with Canada Revenue Agency With Regard to Its Conversion From A Trust To A Corporation investment picks
By Tom FairlessNonbinding vote puts pressure on regulators The European Parliament overwhelmingly approved a resolution that calls for a possible breakup of Google Inc. (GOOG) (GOOGL), brushing aside last-minute objections from the U.S. Congress that the move risked politicizing an antitrust investigation.
Sign-up for EU parliament backs call that may break up Google investment picks
2014/11/27
While the Euromold international 3D Printing trade fair is in full swing, Prodways is pleased to announce that its international sales network is expanding through new partnerships.
Sign-up for 3D Printing: Groupe Gorgé Expands Its Sales Network in France and Abroad investment picks
Shareholders Approve Asset Sale & Related Transaction Agreements BEIJING , Nov.
Sign-up for China Digital TV Provides Update on Asset Restructuring investment picks
GUANGZHOU, China, Nov.
Sign-up for CNinsure to Issue New Shares to Employees investment picks
2014/11/27
By Sara Sjolin, MarketWatch Stagecoach rallies after winning East Coast rail contract LONDON (MarketWatch) -- The U.K.'s FTSE 100 index edged higher Thursday, led by gains for banking firm Barclays PLC after a ratings upgrade.
Sign-up for Barclays leads FTSE 100 higher; oil stocks down ahead of OPEC meeting investment picks
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies Evaluation Committee (EC) has recommended that Soliris ® (eculizumab) be commissioned for all patients in England suffering from atypical hemolytic uremic syndrome (aHUS), a severe and life-threatening ultra-rare disorder.
Sign-up for NICE Issues Final Positive Recommendation for National Commissioning of Soliris® (eculizumab) for All Patients with aHUS in England investment picks
By Laura He, MarketWatch Hong Kong stocks retreat after China's industrial profit slips HONG KONG (MarketWatch) -- Japan stocks posted a second straight day of drops on Thursday, as auto makers suffered heavy losses after the U.S. regulators ordered a nationwide recall of air bags made by Japanese company Takata Corp.
Sign-up for Japan stocks decline as auto makers fall investment picks
By Philip van Doorn, MarketWatch Phil van Doorn presents this year's biggest losers in six market sectors On the day before Thanksgiving, it seems appropriate to highlight some of the year's biggest turkeys in the stock market.
Sign-up for UPDATE: Should you pardon these stock market turkeys? investment picks
2014/11/27
Materials Company Ticker Industry Sales per share - past three quarters Sales per share - year earlier Change in sales per share Total return - YTD Avon Products Inc. Household/ Personal Care $14.99 $16.87 -11% -42% Coach Inc. Apparel/ Footwear Retail $11.81 $12.50 -6% -32% Mattel Inc. Recreational Products $11.84 $12.56 -6% -32% Discovery Communications Inc. Class A Media Conglomerates $10.97
Sign-up for UPDATE: Should you pardon these stock market -2- investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0981168001&sourceType=1 http://www.ccnmatthews.com/logos/20090524-tethylo2.JPG GRAND CAYMAN, CAYMAN ISLANDS --
Sign-up for Tethys Petroleum Limited: New Executive Chairman and Board Committee Appointments investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1161760&ProfileId=051205&sourceType=1 CALGARY, AB --
Sign-up for Canadian Overseas Petroleum Limited Liberia Update investment picks
2014/11/27
LOS ANGELES , Nov.
Sign-up for SoCalGas offers holiday tips that can keep customers safe investment picks
NEWTOWN, Pa., Dec.
Sign-up for Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting investment picks
SAN RAFAEL, Calif., Dec.
Sign-up for BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome investment picks
SOUTH SAN FRANCISCO, Calif., Dec.
Sign-up for Sunesis Pharmaceuticals Announces Presentation of Results From Phase 3 VALOR Trial at ASH Annual Meeting investment picks
Durable Responses Observed with Patients on Study for up to Eight Months and Ongoing in Advanced Acute Myeloid Leukemia and Other Blood Cancers SAN FRANCISCO, Dec.
Sign-up for Agios Announces New Data from Ongoing Phase 1 Trial of AG-221 Showing Robust Clinical Activity in Patients with Advanced Hematologic Malignancies investment picks
Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma.
Sign-up for Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting investment picks
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- [TK - to be prepubbed on Friday for Sunday morning - lede may have to be rewritten to account for Friday developments, please update for Friday closing prices] With gas prices at multiyear lows and consumer sentiment at multiyear highs, retail sales data will likely be the main catalyst for stocks this week.
Sign-up for Retail sales data to confirm tone of holiday shopping investment picks
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that it has filed a Clinical Trial Application (CTA) with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases.
Sign-up for Alnylam Files Clinical Trial Application (CTA) for ALN-CC5, an RNAi Therapeutic Targeting Complement C5 in Development for the Treatment of Complement-Mediated Diseases investment picks
2014/12/7
More than 200 UnitedHealthcare employees and volunteers from the Fort Lauderdale area joined yesterday to build a new playground at Jack and Jill Children’s Center.
Sign-up for Volunteers Build Playground at Jack and Jill Children’s Center in Fort Lauderdale investment picks
Martinsried / Munich, Germany, Dec.
Sign-up for MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting investment picks
By Sue Chang, MarketWatch SAN FRANCISCO (MarketWatch) -- Among the companies whose shares are expected to see active trade in Monday's session are Vail Resorts Inc., H&R Block Inc., and Pep Boys.
Sign-up for UPDATE: Vail Resorts, H&R Block earnings in focus investment picks
Results Show Durable Responses in High Risk Patient Population MARTINSRIED, Germany , MUNICH and MONROVIA, Calif.
Sign-up for MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting investment picks
93% (13/14) of evaluable CLL patients treated at dose levels ≥ 800mg of original formulation or any dose of the micronized formulation achieved a > 50% reduction in nodal size (a nodal PR) and 50% (7/14) achieved a partial response per iwCLL (Hallek 2008) criteria 100% (6/6) of CLL and iNHL patients achieving TGR-1202 drug concentrations above 4,000ng/ml responded at the first or second efficacy assessment with at least a nodal PR for CLL or PR for iNHL; Expansion cohorts now open at 800mg QD for CLL and 1200mg QD for iNHL, the dose level that appears to provide patients (3/3) with drug concentrations > 4,000ng/ml No drug related hepatic toxicity or colitis observed with 55 patients treated to date and median time on study of approximately 6 months and some patients on study for over 1.5 years TGR-1202 has been well-tolerated with no dose-related trends in adverse events observed and no MTD reached to date, dose escalation continues now at 1800mg QD SAN
Sign-up for Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma investment picks
2014/12/6
UnitedHealthcare and the 4-H Youth Development Program at the University of Florida are expanding a successful partnership called Eat4-Health that helps tackle obesity by promoting healthy eating and active lifestyles among youth and families.
Sign-up for Florida 4-H and UnitedHealthcare Expand “Eat4-Health” Partnership, Use “Pedal Power” to Help Tackle Obesity and Encourage Healthy Lifestyles Among Youth investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Bonterra Energy Corp. Enters Into An Agreement with Canada Revenue Agency With Regard to Its Conversion From A Trust To A Corporation to Florida 4-H and UnitedHealthcare Expand “Eat4-Health” Partnership, Use “Pedal Power” to Help Tackle Obesity and Encourage Healthy Lifestyles Among Youth
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent